679 studies on GLP-1R mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
The potential introduction of a high-dose semaglutide (Wegovy HD) could offer a new, more potent option for individuals struggling with obesity who may not achieve sufficient weight loss with current treatments. If th…
This feasibility study holds significant promise for improving the management of Atrial Fibrillation (AF) in overweight and obese individuals, a population often facing suboptimal outcomes. The key implication is that…
This research represents a significant step towards personalized medicine in the treatment of obesity and type 2 diabetes. By understanding the genetic underpinnings of GLP-1 RA response, clinicians could potentially …
This research is significant because it addresses a critical health disparity, focusing on Mexican American women who are at elevated risk for type 2 diabetes. Improving beta cell function is a direct strategy to halt…
The study revealed differential impacts on heart failure (HF) risk among incretin-based drug classes. DPP-4 inhibitors were generally associated with a similar risk of HF compared to other oral anti-diabetic drugs; sp…
Understanding the role of hematopoietic stem cells and inflammation in T2D's cardiovascular risk could revolutionize treatment strategies. If semaglutide proves effective in reversing these inflammatory and cellular c…
Understanding the link between neuropathy and semaglutide-induced gastric retention is crucial for optimizing patient care and safety. This research could lead to improved risk stratification for diabetic patients con…
The successful completion of a bioequivalence study is a critical step in the drug development process, particularly for generic versions or new formulations of existing medications. Demonstrating bioequivalence means…
This study provides compelling real-world evidence that oral semaglutide not only improves glycemic control and promotes weight loss but also significantly reduces systemic inflammation in patients at high cardiovascu…
This narrative review is crucial because it synthesizes the current understanding of GLP-1 RAs, suggesting they could be a valuable therapeutic strategy for improving the long-term health of cancer survivors. Given th…
This comprehensive review underscores the significant potential of liraglutide as an effective therapeutic option for obesity, even in off-label scenarios, providing crucial insights for clinical practice. By synthesi…
The potential for Liraglutide to address both nicotine dependence and weight management simultaneously is significant, as weight gain is a common barrier to successful smoking cessation. This dual-action approach coul…
This Phase 4 clinical trial provides robust evidence reinforcing that liraglutide, a GLP-1 receptor agonist, is effective in reducing systolic blood pressure in patients with Type 2 diabetes and co-existing hypertensi…
This Phase 1 trial is crucial for understanding the fundamental mechanisms by which liraglutide exerts its metabolic effects in obese individuals, even without specific outcome data in the abstract. By clarifying its …
This Phase 3 study is critical because it directly compares two of the most promising pharmacological approaches for obesity management, potentially establishing a new standard of care. The results will provide invalu…
This study is crucial because it addresses a highly underserved patient group: individuals with severe obesity and multimorbidity who cannot undergo bariatric surgery. The findings could establish a new, effective tre…
Understanding the specific metabolic changes induced by CagriSema versus diet-induced weight loss is crucial for optimizing obesity treatment strategies. If CagriSema demonstrates superior or distinct metabolic benefi…
This study provides compelling evidence that semaglutide could be a groundbreaking treatment option for individuals struggling with Alcohol Use Disorder, particularly those with comorbid obesity. Given the high global…
The preservation of bone health during weight loss is a critical consideration, especially for postmenopausal women who are already susceptible to bone density loss and fracture risk. This study is significant because…
This study provides compelling evidence that GLP-1 medicines may offer substantial benefits beyond their primary role in weight loss and metabolic health. The observed improvements in mental health, eating disorder sy…
The findings from this review are highly significant, suggesting that modern antidiabetic drugs offer more than just blood sugar control. They may directly improve outcomes for patients with Peripheral Arterial Occlus…
This finding suggests that initiating Tirzepatide in patients with type 2 diabetes who are new to GLP-1 receptor agonists may offer a distinct and superior advantage in improving liver health, specifically regarding f…
This mathematical modeling study provides crucial insights into the long-term physiological adaptations that lead to the weight loss plateau observed with GLP-1 receptor agonists. Understanding these energy balance dy…
This review represents a conceptual shift in T2D management, proposing that cognitive preservation should become an explicit therapeutic objective, integrated with metabolic control. The identification of existing glu…
This research introduces a groundbreaking approach to treating obesity and diabetes by simultaneously targeting multiple metabolic pathways. By combining GLP-1R, GIPR, and PPARα/γ/δ agonism, this strategy could offer …
These findings are highly significant as they indicate that Lotiglipron has a low propensity for drug-drug interactions with a broad range of commonly used medications. This favorable DDI profile simplifies its potent…
This comprehensive review is critically important as it establishes a robust scientific rationale for further investigating GLP-1 RAs as a novel and potentially transformative therapeutic strategy for psoriasis, espec…
These findings are highly significant, suggesting a novel therapeutic avenue for addressing anhedonia and motivational deficits in Major Depressive Disorder, symptoms that are notoriously difficult to treat with exist…
This study reveals a notable disparity in the utilization of GLP1RAs among individuals with multiple sclerosis who possess cardiometabolic comorbidities that would warrant such treatment. The findings underscore the i…
The findings from this study, once published, could significantly advance our understanding of GLP-1 agonists beyond weight loss, specifically in treating binge eating disorder. If Liraglutide proves effective, it cou…
This Phase III comparative trial is significant because it directly compares three different GLP-1 RA formulations, potentially providing crucial data to guide treatment selection for obese patients. The findings coul…
PCOS is a complex condition with significant unmet needs, particularly for obese and infertile women who struggle with its multifaceted symptoms. If liraglutide demonstrates superior or even comparable efficacy to met…
If successful, this line of research could reposition GLP-1 agonists as potential neuroprotective agents, expanding their therapeutic utility beyond metabolic disorders. The findings, had they been positive, could hav…
This foundational Phase 1 study was critical in establishing the initial safety and pharmacokinetic profile of liraglutide, a drug that later became a cornerstone in the treatment of Type 2 Diabetes and obesity. The p…
The development of CagriSema is significant because it combines two potent mechanisms: Cagrilintide (an amylin analog) and Semaglutide (a GLP-1 receptor agonist), potentially offering synergistic effects for greater w…
Understanding patient experience, especially regarding injection site pain, is crucial for improving adherence to long-term treatments for conditions like Type 2 Diabetes and obesity. If one GLP-1 agonist consistently…
The insights gleaned from this large-scale, multi-country observational study will be invaluable for understanding the real-world effectiveness and safety profile of semaglutide for weight management. This data will h…
This Phase 4 pragmatic trial is crucial because it provides real-world evidence on semaglutide's long-term performance against a broad spectrum of existing Type 2 Diabetes treatments. Such data helps clinicians and pa…
The successful completion of this Phase 1 safety and tolerability study is a pivotal step for LY3841136 and its potential role in obesity treatment. If LY3841136 proves to be safe and effective in combination with tir…
The findings from this study, once published, will be crucial for understanding the full therapeutic potential of incretin-based therapies beyond current GLP-1 receptor agonists. If the combined GIP and GLP-1 activati…
This study provides crucial reassurance for both clinicians and patients regarding the dermatologic safety of GLP-1 RAs, a widely prescribed class of drugs for type 2 diabetes. The findings support the continued use o…
This study provides crucial evidence suggesting that Tirzepatide offers superior weight loss efficacy compared to oral semaglutide, which can significantly inform clinical decision-making for managing overweight and o…
This case report carries significant clinical implications, particularly for endocrinologists and primary care providers prescribing tirzepatide to patients with complex endocrine histories. The finding underscores th…